The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2020Targeting of the Raphe-Cortical Pathway to Reduce Levodopa-Induced Psychosis
Study Rationale:
Parkinson’s disease is best known as a movement disorder, yet non-motor symptoms such as anxiety, depression and psychosis afflict over 50 percent of patients and severely impact... -
Research Grant, 2022Identifying Novel Target Genes and Compounds for Controlling the Motor Symptoms of Parkinson’s Disease
Study Rationale: Understanding neurological conditions has been among the most difficult challenges in modern medicine. The brain contains more than 86 billion nerve cells that form the neural...
-
Dopamine-Non-Responsive Symptoms of Parkinson's Disease, 2006Non-dopaminergic imaging biomarkers as tools for early PD - testing the Braak Hypothesis
Many recent studies have suggested that we need to expand research in Parkinson's disease to study symptoms other than the typical motor symptoms of tremor, slowness of movements, stiffness, and...
-
Therapeutic Pipeline Program, 2016Cognitive Behavioral Therapy for Anxiety Disorders in Parkinson's Disease
Study Rationale:
Anxiety disorders occur in up to 35 percent of people with Parkinson's disease and can have a negative impact on gait, involuntary movements, motor fluctuations and quality of life... -
Improved Biomarkers and Clinical Outcome Measures, 2016Identification of Tear Biomarkers for Individuals with Parkinson's Disease
Study Rationale:
Prior to the appearance of classic movement abnormalities like tremor and slowness, those with Parkinson's suffer from non-motor symptoms, such as altered function of the... -
Research Grant, 2015Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease Supplement
Study Rationale:
STATegics has discovered small molecules that selectively activate the tissue-protective erythropoietin (EPO) receptor, but not the EPO receptor that plays a role in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.